ABSTRACT
INTRODUCTION
Cocrystals can be defined as crystalline materials consist of two or more different components (or commonly called multicomponent crystals). For the pharmaceutical cocrystals, one component is an active pharmaceutical ingredient and other components are called as coformers. Cocrystals have gained considerable interest in pharmaceutical research due to its ability to improve physicochemical characteristics of an API such as such as mechanical behavior, compressibility, solubility, dissolution rate, moisture stability, and bioavailability of drugs with their chemical structure unchanged.
1,2 In a short time span cocrystals are of the interest of the researchers because fast forward to 2015 and the first example of a pharmaceutical ionic cocrystal drug was approved by the US-FDA in accordance with its cocrystal guidance paper for drug substances in 2012 -2013. 3 Entresto is a novel drug launched by Novartis for the treatment of chronic heart failure with the composition monosodium sacubitril, disodium valsartan, and water. Other examples include escitalopram oxalate.
4 a marketed drug in a crystal form that is composed of protonated escitalopram cations, water molecules, oxalate dianions, and diprotonated oxalic acid molecules. The anti-diabetes drug Ertugliflozin.
5 currently in phase III clinical development is a cocrystal with 5-oxo-proline. Fenofibrate is a neutral, lipophilic compound that is practically insoluble in water, making it challenging to consistently achieve therapeutic levels. 6 Our previous investigation showed nicotinamide forms stable cocrystals theoretically and practically with fenofibrate with improved dissolution rate.
7
In general, fenofibrate products can be grouped with regard to their food effects. For example, fenofibrate formulations that should be taken with meals include non-micronized tablets (Fenoglide ®, Lofibra®, generic), micronized capsules (Lofibra® and generic), micro coated micronized tablets (Lofibra®), and fenofibrate hard gelatin capsules (Lipofen®). Fenofibrate formulations that can be taken with or without meals include nanoparticle tablets (Tricor®), IDD-P tablets (Triglide ®), micronized capsules (Antara®), and the choline salt of fenofibric acid (Trilipix®) in a dosage range of 40 to 200 mg.
8
Literature reveals that Fenofibrate (FNO) shows poor flowability and compaction properties. To enhance the compressibility spherical crystallization, highly plastic granules. 9 and melt sonication techniques has been reported. 10 Cocrystallization of the drug powder to control the crystal packing and modulate tabletability which describes the capacity of a powder to be transformed into a tablet in a broader manufacturing perspective and compaction which enables bonding between particles are important improvement at the preformulation stage. The objectives of present investigation were to formulate cocrystals of fenofibrate with nicotinamide by solution cocrystallization technique, solid state characterization of cocrystals by FTIR, PXRD and Raman spectroscopy and to evaluate cocrystals for tableting performance.
MATERIALS AND METHODS

Materials
Fenofibrate was obtained as a gift sample from Alembic pharma, Pvt.Ltd. Vadodara. Nicotinamide were procured from Loba Chemie Pvt. Ltd. Mumbai. All other chemicals were of analytical grade.
Preparation of Cocrystals by Solution crystallization technique
Fenofibrate and nicotinamide were weighed in 1:1 molar ratio, dissolved in 20 ml of ethanol with sonication. The saturated solution was kept overnight to evaporate solvent. The crystals were obtained after evaporation of ethanol; crystals were allowed to dry in the air.
3
Fourier Transform Infrared spectroscopy (FTIR)
IR spectroscopy was conducted using a Shimadzu FTIRAffinity-1S Spectrophotometer (Shimadzu) and the spectrum was recorded in the wavelength region of 7800-350 cm -1 .The procedure consisted of dispersing a sample (drug alone, or prepared cocrystals) in KBR.
Powder X-Ray Diffraction Studies (P-XRD)
The X-ray diffraction patterns of pure drug and the optimized crystals formulation were recorded using Bruker analytical X-ray diffraction (D2 Phase, Bruker) (Germany) with a copper target over the interval of 5-700 2θ -1 . The conditions were voltage 20kV, current 30 mA, scanning speed 20 /min, temperature of acquisition: room temperature, detector: scintillation counter detector, sample holder: non-rotating holder. 
Raman Spectroscopy
The Raman spectra of the pure drug and prepared formulations were recorded in the spectral range of 0-5000 cm−1 using a Raman spectrometer (Bruker MultiRAM, Germany Make) equipped with an Nd: YAG laser source with an at excitation wavelength of 1064 nm and resolution 4 cm −1 .
Tableting Studies
Approximately 250 mg of powder was manually filled into a KBR press die and compressed at predetermined pressures (1 to 2.5 tons) to get flat-faced round tablets (8 mm) diameter, and thickness was measured by using digital venire caliper. The hardness was measured by using Monsanto Hardness Tester. The prepared formulations were also evaluated for Micromeritic properties
RESULTS AND DISCUSSION
Fourier Transform Infrared spectroscopy (FTIR)
The result of FTIR revealed considerable changes in the IR peaks of fenofibrate in prepared co-crystals when compared to pure drug thereby indicating the presence of hydrogen bonding in the co-crystals as shown in Table 1 . Specific FNO peaks were observed at 2982cm -1 indicates aromatic C-H stretching, peak at 1587 cm-1 indicates C=O stretching whereas, peaks at 1241cm -1 and 1087cm -1 indicates aralkyl and dialkyl ether C-O stretching respectively. Also, peak at 757cm-1 indicates presence of halogen-hydrogen interaction. Specific nicotinamide peaks are also observed at 3151.69cm
-1 and 1726.29cm -1 indicating presence of aromatic -NH2 group, CN-stretching and -C=O stretching respectively. In case of co-crystals prepared by 1:1 F+N and 1:2 F+N methods induces interaction which is indicated by appearance of characteristics peak of aromatic -NH2 group at 3151.69 cm -1 that might be involved in the interaction as shown in Figure 1 . Those phenomena may be caused by the hydrogen bond interactions involved in co-crystal formation which changes the symmetry characteristic.
Powder X-Ray Diffraction Studies (P-XRD)
PXRD of all powders showed intense sharp diffraction peaks without amorphous halo observed. The PXRD pattern of fenofibrate as shown in Figure 2 Figure 2 . This revealed a characteristic diffraction pattern, which differed from those of the two individual components. Hence shifting of the peaks has been observed in formulations. This shifting is a clear indication of formation of new phase's i.e. cocrystals. 11, 12 as confirmed from FTIR.
Raman Spectroscopy
The fenofibrate showed Raman bands at 1600cm -1 and 1650cm -1 for aromatic chain vibrations, C=O functional group respectively. The C=C bond is always strong and very reliable. "To form a salt with amine bases the carbonyl group bands shift to lower side by 30-40 cm -1 ". Such type of shifting has not been observed with formulations so it confirms the formed phases are cocrystals. The C-H stretching region in between (3000-2850 cm-1) is a very good diagnostic bond for the presence of the aldehyde functional group. 13, 14, 15 Similar to FTIR, some peak shift also take place for Raman spectra which can be attributed to intermolecular hydrogenbonding. The results are mentioned in Table 2 and Figure 3 .
Tableting Studies
The Table 3 shows among all the formulations the 1:1 and 1:2 ratios of formulations showed better micromeritic properties. The pure fenofibrate showed good angle of repose but moderate type of Hausner's ratio 1.399 and the having poor Carr's index 28.52 %.
16,17
The hardness and thickness of tablet at different applied pressure was determined. The 1:2 ratio based cocrystals are very useful in the formulation of stable tablet than pure drug. The 1:2 ratios of cocrystals of fenofibrate with nicotinamide showed better thickness and hardness properties among those formulations. The order of tableting performance 1:2 ratio cocrystals > 1:1 ratio cocrystals > Recrystallized nicotinamide > Nicotinamide >> Recrystallized Fenofibrate >> Fenofibrate as shown in Table 4 and 5. At any given compaction pressure, the tablet tensile strength of the co-crystal was always greater than that of pure fenofibrate and nicotinamdie. The different mechanical properties of Fenofibrate, Nicotinamide, and their 1: 1 co-crystal originate from differences in crystal packing. Fenofibrate crystals, which contain three dimensional hydrogen bonded networks, may exhibit low plasticity and high resistance to deformation. 
CONCLUSION
The cocrystals of antihyperlipedimic drug, fenofibrate with coformer nicotinamide have been successfully prepared. Cocrystals gives reliable thickness and hardness of the tablets. The cocrystal displayed superior tableting performance. This might be due to the co-crystals, containing hydrogen-bonded two dimensional flat slip planes exhibit higher plasticity.
